US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

474.63

+10.602.28%

Number of Gainers:4

Number of Losers:1

Number of Flat:- -

PE:- -

High:486.45

Open:463.92

Low:463.92

Close:464.04

Volume:106.06M

Turnover:267.37M

Market Cap:10.50B

Float Cap:9.71B

Loading ...

CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings Summary

Switzerland's CRISPR Therapeutics Q1 net loss narrows

CRISPR Therapeutics Q1 net loss narrows to $122.9 million; revenue hits $43 million

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress

Simply Wall St.

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

Intellia awards 208,850 inducement RSUs to 43 new employees under 2024 plan

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline

Intellia Therapeutics announces annual shareholder meeting notice

Sangamo presents neurology epigenetic regulation data at ASGCT annual meeting

Lexeo Therapeutics appoints Laura Sepp-Lorenzino to board

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

BRIEF-Sangamo Therapeutics To Transition Common Stock To Otcqb Venture Market On May 5, 2026

Sangamo shares set to move to OTCQB as Nasdaq delists stock May 5

Sangamo Therapeutics Inc - to Transition Common Stock to Otcqb Venture Market on May 5, 2026

THOMSON REUTERS

Press Release: Morningstar Reaches New Milestone in the CRSP Acquisition, Rebranding CRSP Market Indexes to Morningstar Indexes

BUZZ-Gene-editing firm Intellia falls on $180 mln stock sale

Intellia Therapeutics Inc - Public Offering Price Set at $10.75 per Share

THOMSON REUTERS

Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":474.63248,"timestamp":1777924799999,"preClose":464.03525,"halted":0,"volume":106064756,"delay":0,"changeRate":0.022837,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":10.597229,"latestTime":"05-04 16:00:00 EDT","open":463.91913,"high":486.4496,"low":463.91913,"amount":267371490.170596,"amplitude":0.048553,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777939200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.605177,"peRate":-7.379349,"turnoverRate":0.138636,"increases":4,"decrements":1,"flats":0,"marketCap":10500055840,"floatMarketCap":9706604736},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":486.4496,"amplitude":0.048553,"preClose":464.03525,"low":463.91913,"pbRate":"2.605177","latestPrice":474.63248,"volume":106064756,"delay":0,"open":463.91913,"prevYearClose":431.70972,"prevWeekClose":464.0353,"prevMonthClose":466.7848,"prevQuarterClose":411.156,"fiveDayClose":454.0163,"twentyDayClose":424.4774,"sixtyDayClose":396.7108,"secType":"PLATE","market":"US","turnoverRate":0.138636,"peRate":-7.379349,"marketCap":10500055840,"floatMarketCap":9706604736,"timestamp":1777924799999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":4,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633961520","title":"CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633961520","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633961520?lang=en_us&edition=fundamental","pubTime":"2026-05-05 05:09","pubTimestamp":1777928946,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings SummaryCRISPR Therapeutics AG CRSP.OQ reported a quarterly adjusted loss of $1.28 per share for the quarter ended March","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H2DT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","LU1861559042.SGD","BK4585","BK4556","CRSP","BK4139","BK4588","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633699999","title":"Switzerland's CRISPR Therapeutics Q1 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2633699999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633699999?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:43","pubTimestamp":1777927432,"startTime":"0","endTime":"0","summary":"Switzerland's CRISPR Therapeutics Q1 net loss narrowsOverviewSwitzerland-U.S. gene-editing biotech's Q1 revenue missed analyst expectationsQ1 EPS was -$1.28; net loss narrowed from prior yearOperating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL1N41H132:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4611","BK4556","BK4139","CRSP","LU1861559042.SGD","LU1861558580.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969311","title":"CRISPR Therapeutics Q1 net loss narrows to $122.9 million; revenue hits $43 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969311","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969311?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:39","pubTimestamp":1777927147,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics posted a net loss of USD 122.9 million for first-quarter 2026, narrowing from USD 136 million a year earlier, while CASGEVY revenue totaled USD 43 million.Cash, cash equivalents, and marketable securities climbed to USD 2.44 billion as of March 31, up from USD 1.98 billion at year-end 2025, driven primarily by USD 585.4 million of net proceeds from issuance of convertible senior notes in March.R&D expenses fell to USD 68.6 million from USD 72.5 million, while G&A expenses eased to USD 17.2 million from USD 19.3 million.Collaboration expense, net, declined to USD 45.9 million from USD 57.5 million, on an increase in its share of CASGEVY revenue.More than 500 people globally have initiated the CASGEVY treatment journey, while FDA cleared IND expansion for zugo-cel into autoimmune neurologic diseases and the company reiterated plans to start CTX340 in first-half 2026 and CTX460 in mid-2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbngPty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","SG9999014039.USD","IE00BN0W2W23.USD","LU1861558580.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","IE00BN0W2T93.GBP","LU2210150020.SGD","SG9999014005.SGD","CRSP","IE00B64PRP62.GBP","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","SG9999014013.SGD","LU1861559042.SGD","BK4588","BK4556","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969366","title":"CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969366?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:30","pubTimestamp":1777926600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, May  04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflec","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287176/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","CAT","BK4516","LU1861559042.SGD","CAR","LU1720051108.HKD","LU1861558580.USD","KSA","IE00BD6J9T35.USD","LU0942090050.USD","LU0251142724.SGD","LU2237438978.USD","LU0742534661.SGD","LU0251131958.USD","LU2264538146.SGD","SLE","LU0963586101.USD","LU1064131342.USD","LU2357305700.SGD","BK4597","BK4556","LU1720051017.SGD","BK4022","UAE","BK4149","BK4520","LU1917777945.USD","LU1974910355.USD","LU1988902786.USD","CRSP","IND","AGT","ITP","LU0868494708.USD","BK4077","FXI","BK4199","BK4611","BK4139","BK4230","BK4532","BK4585","LU2106854487.HKD","LU2543165471.USD","SCD","LU0048573561.USD","IE00BSNM7G36.USD","LU0868494617.USD","LU2023250504.SGD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632467486","title":"A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2632467486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632467486?lang=en_us&edition=fundamental","pubTime":"2026-05-03 01:43","pubTimestamp":1777743803,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) is back in focus after TIME named it among 2026’s 10 Most Influential Health & Life Science Companies, alongside encouraging Phase 1/2 BEACON data in sickle cell disease treatment.\nSee our latest analysis for Beam Therapeutics.\nInvestors appear to be responding to the TIME recognition and encouraging BEACON data, with the 7-day share price return of 13.24% and 30-day share price return of 26.75% pointing to strengthening momentum. The 1-year total shareholder return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/a-look-at-beam-therapeutics-beam-valuation-after-time-recogn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/a-look-at-beam-therapeutics-beam-valuation-after-time-recogn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","PRGS","BK4556","LU1861558580.USD","BK4097","LU1861559042.SGD","BK4505","BK4535","BEAM","TIME","BK4588","BK4139","BK4611","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632626113","title":"Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2632626113","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632626113?lang=en_us&edition=fundamental","pubTime":"2026-05-02 08:11","pubTimestamp":1777680662,"startTime":"0","endTime":"0","summary":"20:06 EDT Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-141k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-141k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKG","BK4535","ARKX","SARK","BK4139","BK4556","BK4585","LU1861559042.SGD","ARKQ","ARKK","ARKW","NTLA","BK4544","BK4588","ARKF","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642289","title":"Intellia awards 208,850 inducement RSUs to 43 new employees under 2024 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642289","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642289?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:01","pubTimestamp":1777665677,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics granted inducement awards to 43 new employees on May 1, 2026.Awards comprised time-based restricted stock units covering 208,850 shares.One-third of RSUs vest annually over three years, subject to continued service.Grants were issued under Intellia 2024 Inducement Plan, as amended.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL5pnjVm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00BGHQF748.EUR","BK4112","BK4588","BK4556","LU1861559042.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","NTLA","LU1861558580.USD","BK4585","LU2210150020.SGD","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","SG9999014021.USD","SG9999014005.SGD","BK4139","IE00BN0W2T93.GBP","BK4535","IE00BN0W2W23.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632464202","title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632464202","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632464202?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:01","pubTimestamp":1777665660,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May  01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3286199/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NTLA","LU1861558580.USD","LU1861559042.SGD","BK4588","BK4535","BK4556","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632640662","title":"Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2632640662","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632640662?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:38","pubTimestamp":1777585102,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics ( ($NTLA) ) has issued an update. On April 28, 2026, Intellia Therapeutics entered into an underwriting agreement with Jeffer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-prices-public-equity-offering-to-fund-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-prices-public-equity-offering-to-fund-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EQR","NTLA","LU1861558580.USD","LU1861559042.SGD","BK4588","BK4535","BK4556","BK4585","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632693666","title":"Intellia Therapeutics announces annual shareholder meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2632693666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632693666?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:21","pubTimestamp":1777580481,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics will hold its annual stockholder meeting online on June 9, 2026.Shareholders will vote on election of three Class I directors to serve until 2029.Ballot also includes ratification of Deloitte & Touche as independent registered public accounting firm for fiscal 2026.Meeting agenda includes non-binding advisory vote on named executive officer compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLb6Rq9x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4535","NTLA","LU1861559042.SGD","LU1861558580.USD","BK4139","BK4556","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631632576","title":"Sangamo presents neurology epigenetic regulation data at ASGCT annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631632576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631632576?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:23","pubTimestamp":1777551820,"startTime":"0","endTime":"0","summary":"Sangamo to present neurology pipeline updates at ASGCT annual meeting May 11-15, 2026, held in Boston with virtual option.Company schedules two poster presentations May 12, 2026, covering zinc finger epigenetic repressors for chronic neuropathic pain and prion disease.Oral presentation set for May 12, 2026, outlining updated data on modular integrase genome integration platform.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLc2Gfdb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210150020.SGD","BK4556","NDAQ","BK4588","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4139","SGMO","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631350106","title":"Lexeo Therapeutics appoints Laura Sepp-Lorenzino to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2631350106","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631350106?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:05","pubTimestamp":1777547139,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics appointed Laura Sepp-Lorenzino to board on April 28, 2026.Board named Sepp-Lorenzino to Science and Technology Committee.Sepp-Lorenzino will serve as director through 2028 annual meeting of stockholders.She has served as principal of genomic medicine consultancy GNMmeds since January 2025.Sepp-Lorenzino previously served as executive vice president, chief scientific officer at Intellia Therapeutics from May 2019 to January 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL4Vnv5Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861558580.USD","BK4585","BK4556","BK4535","LXEO","NTLA","BK4588","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631328508","title":"Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2631328508","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631328508?lang=en_us&edition=fundamental","pubTime":"2026-04-30 11:26","pubTimestamp":1777519562,"startTime":"0","endTime":"0","summary":"23:21 EDT Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-2-4m-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-2-4m-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKQ","BK4535","ARKG","ARKK","LU1861559042.SGD","ARKF","ARKX","BK4544","BK4585","BK4588","LU1861558580.USD","BK4139","ARKW","NTLA","SARK","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631519373","title":"BRIEF-Sangamo Therapeutics To Transition Common Stock To Otcqb Venture Market On May 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631519373","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631519373?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:09","pubTimestamp":1777464570,"startTime":"0","endTime":"0","summary":"BRIEF-Sangamo Therapeutics To Transition Common Stock To Otcqb Venture Market On May 5, 2026April 29 (Reuters) - Sangamo Therapeutics Inc SGMO.O:SANGAMO THERAPEUTICS INC - TO TRANSITION COMMON STOCK T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C0ZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMO","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631519306","title":"Sangamo shares set to move to OTCQB as Nasdaq delists stock May 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2631519306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631519306?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:09","pubTimestamp":1777464560,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics common stock is set to be delisted from Nasdaq Capital Market due to non-compliance with Nasdaq minimum bid price requirement.Nasdaq trading is expected to be suspended at open May 5, 2026.Sangamo plans to request a Nasdaq hearing to appeal delisting determination, with no stay on the May 5 trading suspension.Company is negotiating multiple potential business development transactions, with updates expected if definitive agreements are executed.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL5TTJ0h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","SG9999014021.USD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SGMO","BK4139","LU2210149790.SGD","SG9999014005.SGD","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4112","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516085","title":"Sangamo Therapeutics Inc - to Transition Common Stock to Otcqb Venture Market on May 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516085","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516085?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:05","pubTimestamp":1777464343,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C0ZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","SGMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516171","title":"Press Release: Morningstar Reaches New Milestone in the CRSP Acquisition, Rebranding CRSP Market Indexes to Morningstar Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516171","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516171?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:00","pubTimestamp":1777464000,"startTime":"0","endTime":"0","summary":"The rebrand of the CRSP indexes, with over $3 trillion in AUM benchmarked, solidifies Morningstar's position as one of the top tier index providers and is an important new milestone in the CRSP integration.Morningstar, Inc. , a leading provider of independent investment insights, has reached a new milestone in its previously completed acquisition of the Center for Research in Security Prices  from the University of Chicago, announcing the rebrand of the CRSP Market Indexes to reflect the Morningstar brand.Added Amelia Furr, president of Morningstar Indexes, \"Now with over $4.2 trillion in assets linked to our benchmarks, including over 370 investment products, Morningstar offers an expansive alternative to legacy index providers. Adding the Morningstar brand to the CRSP indexes is another step in growing global visibility for this high-quality methodology. We are committed to scaling our U.S. index capabilities and extending our reach to more clients across the market and investing eco","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","LU1878469433.USD","BK4556","LU1861558580.USD","BK4588","BK4611","BK4585","BK4112","BK4598","LU1861559042.SGD","MORN","BK4139","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631515776","title":"BUZZ-Gene-editing firm Intellia falls on $180 mln stock sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2631515776","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631515776?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:51","pubTimestamp":1777463469,"startTime":"0","endTime":"0","summary":"BUZZ-Gene-editing firm Intellia falls on $180 mln stock sale** Shares of biopharma Intellia Therapeutics NTLA.O down 8.4% in premarket trading to $12.09 after $180 mln follow-on pricing** Co announces ~16.7 mln shares at $10.75, which is an 18.6% discount to stock's last close** On Mon, NTLA's stock finished session down >4% at $13.04 after co said its experimental gene-editing therapy reduced frequency of swelling attacks in late-stage trial** Following the results, co said to start a rolling submission of its data to seek U.S. FDA's approval of the gene therapy next year** After the bell Mon, NTLA launched $150 mln equity offering to fund clinical development and prepare commercial launch of its lead programs, R&D for other pipeline candidates, potential acquisitions, among other purposes, according to prospectus** Jefferies, Goldman Sachs and Citigroup joint bookrunners** Cambridge, Massachusetts-based NTLA had ~118.1 mln shares outstanding prior to this offering** NTLA's stock edge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL6N41C0QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","IE0004091025.USD","GSX","LU0098860793.USD","BK4588","LU2237443382.USD","LU2237443895.HKD","BK4535","BK4556","LU0128525689.USD","LU1894683348.USD","LU1894683264.USD","JEF","BK4207","BK4585","LU2237443622.USD","LU0096364046.USD","LU2236285917.USD","LU0742534661.SGD","LU0314106906.USD","LU2750360997.AUD","LU0130102774.USD","IE0004086264.USD","LU1244550221.USD","LU0130517989.USD","NTLA","LU0980610538.SGD","LU0048573561.USD","LU0648001328.SGD","LU2360032135.SGD","LU1868837136.USD","LU1244550494.USD","IE0002270589.USD","LU2125154778.USD","BK4504","BK4559","LU2237443978.SGD","LU2462157665.USD","LU1804176565.USD","LU1366192091.USD","LU0251142724.SGD","LU2237438978.USD","LU1244550577.SGD","LU0310800965.SGD","LU0477156953.USD","LU0251131958.USD","BK4552","LU0320765646.SGD","LU1506573853.SGD","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631259055","title":"Intellia Therapeutics Inc - Public Offering Price Set at $10.75 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2631259055","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631259055?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:00","pubTimestamp":1777460403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUA74MRJG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","BK4535","BK4139","NTLA","BK4588","BK4585","LU1861558580.USD","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631598195","title":"Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2631598195","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631598195?lang=en_us&edition=fundamental","pubTime":"2026-04-29 09:18","pubTimestamp":1777425531,"startTime":"0","endTime":"0","summary":"In late April 2026, Intellia Therapeutics reported positive topline data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, and began a rolling biologics license application with the FDA for this one-time in vivo CRISPR treatment.\nThe HAELO trial showed lonvo-z cut hereditary angioedema attacks very sharply versus placebo, supporting Intellia’s push to bring what could become the first in vivo CRISPR-based gene editing therapy to market.\nNext,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-down-138-after-positive-ph","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-down-138-after-positive-ph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0205193047.USD","IE00B19Z6F94.USD","BK4139","LU0012050646.USD","LU1169589451.USD","LU1861558580.USD","BK4588","BK4585","BK4535","IE00B64QTZ34.USD","IE0034390439.USD","LABU","HAE","LU1861559042.SGD","BK4556","LU0205194284.USD","BK4198","LU0106261612.USD","IE00BLDYK493.USD","LU1169590202.USD","NTLA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}